The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Impact of preoperative statin medication on long-term outcomes after pancreatoduodenectomy for ductal adenocarcinoma: an international multicentric cross-sectional study
Open accessAbstract
Purpose: Statin treatment has been shown in certain population studies and meta-analyses to improve survival of patients with pancreatic ductal adenocarcinoma (PDAC). This study assessed if patients with statin treatment had better overall survival (OS) and disease-free survival (DFS) after upfront pancreatoduodenectomy for PDAC. Methods: Consecutive PDAC patients were retrospectively collected from three centers in Europe and USA (study period: 2000–2017). Adult patients who underwent upfront pancreatoduodenectomy and survived the first 90 postoperative days were included. Patients with metastasis at diagnosis or with macroscopic incomplete resection were excluded. Patients were considered under statin if started at least one month before pancreatoduodenectomy. Survival rates were calculated using Kaplan–Meier method and compared with log-rank test. Results: A total of 496 patients were included. Median age was 67 years (IQR 59–75), 48% (n = 236) were women, and 141 patients (28%) received statin treatment already preoperatively. Patients with and without statin treatment were comparable in terms of demographics and pre-/intraoperative characteristics, except for age and pre-existing diabetes. Median OS and DFS were similar in patients with and without statin treatment (OS: 29, 95% CI 22–36 vs. 27 months, 95% CI 22–32, p = 0.370, DFS: 18, 95% CI 14–22 vs. 16 months, 95% CI 14–18, p = 0.430). On multivariable Cox regression, lymph node involvement (HR 1.9, 95% CI 1.6–2.2, p < 0.001), tumor differentiation (HR 1.3, 95% CI 1.1–1.6, p = 0.003), and postoperative chemotherapy (HR 0.5, 95% CI 0.4–0.7, p < 0.001) were predictors of OS, whereas statin treatment was not a prognostic factor (HR 0.9, 95% CI 0.7–1.2, p = 0.376). Conclusion: In this international cohort of PDAC patients, statin treatment did not influence survival after upfront pancreatoduodenectomy. Nodal involvement, tumor differentiation, and postoperative chemotherapy were independent predictors of OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence from large population-based cohorts demonstrates mixed results regarding the relationship between statin use and PDAC incidence or survival outcome, with some cohorts showing variable protective effects and others showing a survival benefit of statin exposure, as shown in Table 1”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Joliat et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“No statistically significant differences in OS and DFS between the patients treated with statins and those never treated with statins were reported (Joliat et al., 2023).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Joliat et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
Self-citationPostoperative pancreatic fistula: An international study group (ISGPF) definition
Bassi, C., Dervenis, C., Butturini, G., Fingerhut, A., Yeo, C., Izbicki, J., Neoptolemos, J., Sarr, M., Traverso, W., & Buchler, M. (2005) · Surgery · doi:10.1016/j.surg.2005.05.001 · Cited by 4,277
Wente, M. N., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., Traverso, L. W., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.05.005 · Cited by 3,053
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 1×
“Despite recent advances in surgical techniques and perioperative care, the long-term outcomes for patients with pancreatic cancer remain dismal (Conroy et al. 2018).”
BackgroundWente, M. N., Veit, J. A., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.02.001 · Cited by 2,616
The Comprehensive Complication Index: A Novel Continuous Scale to Measure Surgical Morbidity
Slankamenac, K., Graf, R., Barkun, J., Puhan, M. A., & Clavien, P.-A. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318296c732 · Cited by 1,773
Horan, T. C., Gaynes, R. P., Martone, W. J., Jarvis, W. R., & Emori, T. G. (1992) · Infection Control & Hospital Epidemiology · doi:10.1017/s0195941700015241 · Cited by 1,396
Horan, T. C., Gaynes, R. P., Martone, W. J., Jarvis, W. R., & Emori, T. G. (1992) · Infection Control and Hospital Epidemiology · doi:10.2307/30148464 · Cited by 1,167
Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer
Emilsson, L., García-Albéniz, X., Logan, R. W., Caniglia, E. C., Kalager, M., & Hernán, M. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2752 · Cited by 188
The Innovative Potential of Statins in Cancer: New Targets for New Therapies
Di Bello, E., Zwergel, C., Mai, A., & Valente, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00516 · Cited by 105
Cited by
The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
Peduzzi, G., Archibugi, L., Farinella, R., Pisani, R. P. D. L., Vodičková, Ľ., Vodička, P., Kraja, B., Sáinz, J., Bars‐Cortina, D., Daniel, N., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.004 · Cited by 39
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer
Michels, A. K., Calderon, S. E., Nghiem, E., Zimmer, E., Santana, L. S., Singh, R., Eiseler, T., Allgöwer, C., Tong, G., Wu, S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.09.027 · Cited by 2
Lipids, lipid-lowering drug target genes and pancreatic cancer: a Mendelian randomization study
Zhan, Y., Zhang, K., Fan, Y., Lin, S., Wu, J., Xu, H., & Xu, H. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01866-7 · Cited by 2
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
Statin Medication: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsarad97359b1
Metadata
- Authors
- Joliat, G.-R., Gaspar-Figueiredo, S., Labgaa, I., Vrochides, D., Perinel, J., Adham, M., Demartines, N., & Schäfer, M.
- Affiliations
- University of Bern (CH)
- Carolinas Medical Center (US)
- Hôpital Edouard Herriot (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Joliat, Gaëtan-Romain
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2023-09-23
- Volume
- 149
- Issue
- 19
- Pages
- 17007-17014
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC10657279
- OpenAlex
- W4386980322
- Cited by
- 3
- References
- 19
- Citations by year
- 2026: 1 · 2025: 2
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- Funders
- University of Lausanne
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- statins, pancreatic ductal adenocarcinoma, pancreaticoduodenectomy, preoperative statin therapy, overall survival, disease-free survival, prognostic factors, lymph node involvement, tumor differentiation, postoperative chemotherapy, resectability, postoperative complications, postoperative mortality, long-term outcomes, predictors of recurrence, mortality risk factors, predictors of quality of life
- MeSH terms
- Adenocarcinoma, Adult, Aged, Cross-Sectional Studies, Female, Humans, Male, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Pancreaticoduodenectomy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of preoperative statin medication on long-term outcomes after pancreatoduodenectomy for ductal adenocarcinoma: an international multicentric cross-sectional study. https://app.cochat.ai/papers/10.1007/s00432-023-05426-2
- The paper
- Joliat, G.-R., Gaspar-Figueiredo, S., Labgaa, I., Vrochides, D., Perinel, J., Adham, M., Demartines, N., & Schäfer, M. (2023). Impact of preoperative statin medication on long-term outcomes after pancreatoduodenectomy for ductal adenocarcinoma: an international multicentric cross-sectional study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-05426-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.